Skip to main content
Figure 4 | Cardiovascular Diabetology

Figure 4

From: Telmisartan ameliorates insulin sensitivity by activating the AMPK/SIRT1 pathway in skeletal muscle of obese db/db mice

Figure 4

Effects of telmisartan on the AMPK/SIRT1 pathway in C2C12 myocytes. C2C12 myocytes were treated with vehicle or 0.01–0.1 μM telmisartan and the level of Sirt1 mRNA measured by RT-PCR (A). On day 5, C2C12 myocytes were treated with 0.1 μM telmisartan or 2 mM 5-aminoimidazole-4-carboxamide ribonucleoside (AICAR), an activator of AMP-activated protein kinase (AMPK), for 60 min, after which total cell lysates were subjected to western blot analysis using antibodies specific for Phospho-AMPK and total AMPK (B). NAD+, NADH content, and NAD+/NADH ratio (C) in C2C12 myocytes treated with telmisartan or AICAR (0.5 mM). Values shown represent means ± S.E (n = 3-5). *p < 0.05 vs. 0, by Fisher’s PLSD.

Back to article page